ALL POLICIES
- Open Access Policy
- Plagiarism Policy
- COPE Recommendation for Plagiarism
- Copyright Policy
- Rights and Grants to the Author
- Licensing Policy
- COPE Recommendation for Conflict of Interest
- Publication Ethics and Malpractice Statement
- APC Waiver Policy
- Withdrawal Policy
- Human and Animal Rights Policy
- Errata, Retractions and Corrigenda Policy
- Digital Preservation
- Advertisement Policies
- Editorial Policies
- Conflict of Interest and Financial Disclosures
- Participant/Patient Privacy and Informed Consent
- Data Sharing Policy for IRJP
1. Open Access Policy
The IRJP embraces the principles of open access, ensuring that all published research is freely available to anyone with internet access. The journal is committed to ensuring that authors' work is disseminated widely and that there are no financial barriers to reading the published content.
This policy ensures that all articles published by IRJP are immediately available online for free, and can be accessed, downloaded, shared, and reused under the terms of the Creative Commons Attribution License (CC-BY). We encourage authors to make their research as accessible as possible, including sharing their datasets and supplementary materials with the public.
Through this approach, the journal aims to promote the dissemination of knowledge and scientific advancements to a global audience, thus fostering collaboration and innovation within the field of pharmacy and pharmaceutical sciences.
2. Plagiarism Policy
IRJP has a zero-tolerance policy for plagiarism. Authors must ensure that their manuscripts are original and not plagiarized. All articles submitted to IRJP are screened for plagiarism using advanced plagiarism detection tools (such as iThenticate or Turnitin).
In the event of detected plagiarism, the manuscript will be rejected immediately. If plagiarism is discovered after publication, the article will be retracted, and the appropriate actions will be taken in accordance with COPE guidelines. Authors must ensure proper citation and attribution of all sources, ideas, and data used in their research.
We encourage authors to maintain high academic integrity and uphold ethical standards in all stages of the publishing process, from writing the manuscript to the submission and peer-review stages.
3. COPE Recommendation for Plagiarism
The IRJP adheres to the recommendations set forth by the Committee on Publication Ethics (COPE) regarding plagiarism. COPE provides a flowchart and guidelines for handling plagiarism cases, ensuring transparency and fairness in the investigative process.
If plagiarism is suspected, the journal follows a structured approach, starting with an investigation into the extent of the plagiarism. Depending on the severity, actions may include manuscript rejection, correction of the published article, or retraction of the paper. IRJP is committed to maintaining the highest standards of integrity in research publication.
4. Copyright Policy
Upon acceptance of an article, the copyright is transferred to the International Research Journal of Pharmacy. Authors retain the right to use their article for academic purposes, including sharing it at conferences and in other publications, as long as proper attribution is given to the original publication.
Authors are encouraged to disseminate their work widely, and the IRJP permits authors to upload the final published version of their manuscript to institutional repositories and personal websites, provided they follow the appropriate attribution guidelines.
The copyright transfer ensures that the journal retains control over the distribution, reproduction, and modification of the article, enabling the journal to preserve and disseminate the work efficiently to a broad audience.
6. Licensing Policy
All articles published in the IRJP are made available under the Creative Commons Attribution-NonCommercial 4.0 International License. This means that readers may share and adapt the work, provided they give appropriate credit and do not use the work for commercial purposes.
By applying this license, the journal supports open access and ensures that published research can be freely accessed, shared, and repurposed for educational and non-commercial purposes. Authors are required to agree to this license upon submitting their manuscript for publication.
7. COPE Recommendation for Conflict of Interest
In accordance with the guidelines established by COPE, the IRJP requires authors, reviewers, and editors to disclose any potential conflicts of interest that may influence the research or the publication process.
Conflict of interest can arise from financial, personal, or professional relationships that may impact an individual's objectivity. Disclosure of any such conflicts is mandatory and helps maintain the integrity and transparency of the publication process.
8. Publication Ethics and Malpractice Statement
The IRJP adheres to a strict code of ethics in the publication process. This includes transparency in the peer review process, avoiding falsification or fabrication of data, and ensuring the confidentiality of submitted manuscripts.
We support the COPE guidelines and are committed to addressing any allegations of misconduct in research publication, including plagiarism, authorship disputes, and falsification of data. All such cases will be dealt with transparently and in accordance with COPE’s recommended procedures.
9. APC Waiver Policy
The IRJP offers waivers of the Article Processing Charges (APCs) for authors from low-income countries or those who cannot afford to pay the fees. This policy ensures that the financial constraints of authors do not prevent them from publishing their research.
Requests for waivers are reviewed on a case-by-case basis and are granted at the discretion of the editorial board. Waivers are typically awarded for authors from regions with limited funding opportunities or where the cost of APCs may pose a barrier to publication.
10. Withdrawal Policy
Authors may request to withdraw their manuscript at any point before it has been accepted for publication. Once the article has entered the peer review process, withdrawal requests will be considered only in exceptional cases.
After acceptance, manuscripts can only be withdrawn under specific circumstances, such as serious ethical issues or inadvertent errors in the manuscript. If the manuscript has already been published, retraction will be considered.
11. Human and Animal Rights Policy
The IRJP adheres to strict ethical standards regarding the treatment of human and animal subjects in research. All research involving human participants must comply with the ethical principles outlined in the Declaration of Helsinki. Researchers must obtain informed consent from participants, ensuring that their participation is voluntary and based on a clear understanding of the study.
For research involving animals, the IRJP requires compliance with the 3Rs (Replacement, Reduction, and Refinement) principles to ensure humane treatment. All studies must have approval from relevant ethics committees or institutional review boards, ensuring the welfare of both human and animal subjects throughout the research process.
The journal may request documentation of ethical approval for studies involving human or animal subjects and reserves the right to reject submissions that do not meet these standards.
12. Errata, Retractions and Corrigenda Policy
In the event of significant errors or inaccuracies in a published article, the IRJP follows a transparent process for issuing errata, corrigenda, and retractions. Minor errors that do not affect the core findings of a study may be corrected through a corrigendum, while significant errors that impact the study's results may require a full retraction of the article.
If an article is retracted, the journal will provide a clear and transparent explanation, including the reason for retraction. This ensures that the academic record remains accurate, and any misleading or incorrect information is appropriately addressed. IRJP is committed to maintaining the integrity of the scientific record and promptly addressing any errors or misconduct.
All errata, corrigenda, and retractions are published in the same way as articles and are linked to the original publication to maintain clarity and accuracy.
13. Digital Preservation
The IRJP is committed to ensuring the long-term preservation and accessibility of all published content. To this end, the journal collaborates with international digital repositories and archiving systems to ensure that research articles remain accessible for future generations.
In addition to ensuring that published articles are freely accessible, the IRJP adheres to best practices for digital preservation, including regular backups and the use of widely accepted file formats that remain accessible over time. The journal’s content is also indexed in major databases and repositories to facilitate continued access and visibility.
As part of our commitment to digital preservation, we also make efforts to ensure that metadata associated with each article is correctly stored and easily retrievable. The journal is committed to complying with international standards and recommendations on digital preservation.
14. Advertisement Policies
The IRJP does not accept any form of commercial advertising in its published content. The journal maintains an independent editorial policy, and all content is strictly peer-reviewed and free from commercial influence.
Any advertisements related to pharmaceuticals or other products relevant to the research field may only be accepted in accordance with relevant ethical guidelines and applicable laws. The journal’s editorial board will ensure that there is no conflict of interest between advertising and the scientific content published within the journal.
The integrity of the content is paramount, and IRJP ensures that any advertisements, if accepted in future issues, are clearly distinguished from editorial content to avoid any confusion.
15. Editorial Policies
The editorial policies of IRJP are designed to ensure that the journal adheres to the highest standards of academic integrity and transparency. The journal’s editorial board is responsible for managing the peer-review process and ensuring that published articles are of the highest quality.
IRJP follows a rigorous peer-review process to evaluate submissions. Articles are reviewed by independent experts in the field, and authors are required to address reviewer comments before publication. This process helps ensure that only valid, high-quality research is published.
The editorial board also regularly reviews and updates editorial guidelines to maintain transparency and fairness in the publishing process. All editorial decisions are made based on scientific merit, and the journal ensures no editorial bias in accepting or rejecting articles.
16. Conflict of Interest and Financial Disclosures
The IRJP requires all authors, reviewers, and editors to disclose any potential conflicts of interest that might influence the publication process. A conflict of interest could arise from financial interests, personal relationships, or professional affiliations that might be perceived to bias the research or its interpretation.
Authors must provide a statement disclosing any financial support or affiliations with companies or organizations that could be considered a conflict of interest. The same applies to reviewers and editors who may have a stake in the outcome of a manuscript review.
By requiring these disclosures, the IRJP aims to maintain transparency and objectivity in the review and publication process. Any articles submitted without the required conflict of interest disclosures will be rejected or returned for clarification.
17. Participant/Patient Privacy and Informed Consent
The IRJP upholds the highest ethical standards concerning the privacy of participants in research studies. All authors are required to obtain written informed consent from all human participants involved in their research before publishing. This consent must cover the use of participants’ data in the research publication, ensuring that participants understand the purpose of the study and how their data will be used.
Authors must also ensure that participants' identities remain confidential, and personal data is anonymized or de-identified to protect privacy. If personal details or images are included in the publication, explicit consent must be obtained from the individuals involved.
By upholding strict guidelines regarding informed consent and participant privacy, IRJP ensures that all research published is conducted ethically and that participants’ rights are fully protected throughout the process.
18. Data Sharing Policy for IRJP
The IRJP supports open data sharing as a means to enhance scientific research and collaboration. Authors are encouraged to share their raw data, materials, and other supplementary information relevant to their studies. The aim is to foster transparency, reproducibility, and further research in the field of pharmacy and pharmaceutical sciences.
All data shared by authors should be made publicly available in appropriate repositories or as supplementary material alongside the published article. Where possible, authors should ensure that data is presented in formats that facilitate reuse by other researchers.
However, authors must ensure that no sensitive or personally identifiable information is shared unless explicit consent has been obtained from the individuals involved. IRJP encourages the use of recognized data repositories that ensure proper handling, storage, and citation of data.
Authors are also required to include a data availability statement in their manuscripts, detailing how others can access the data associated with their research. This statement should clarify whether data is publicly available, available upon request, or subject to restrictions (such as confidentiality agreements or legal constraints).
